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Abstract: The many diverse functions executed by the central nervous system (CNS) are mirrored in the diverse shapes, 
connections, and firing patterns of its individual neuronal cell types. Furthermore, distinct neurological diseases are the re-
sult of defects in specific neuronal cell types. However, despite the significance of this cellular diversity underlying brain 
function and disease, we know relatively little about the genes that contribute to purposeful differences among regions and 
cell types within the brain. A major challenge in this endeavor is the paucity of markers that define the many regions and 
cell types thought to exist. Cataloging the neuronal cell types and cell- and region-specific marker genes requires novel 
avenues that enable researchers to define gene expression profiles of brain regions and individual neurons and to apply 
this information to understand functional and structural properties in the normal and diseased brain. Functional genomic 
approaches such as gene expression profiling offers the exclusive opportunity to glimpse the detailed inner workings of 
distinct neuronal cell types. Recent studies have applied microarray technology in unique and novel ways to understand 
the molecular mechanisms that underlie such neuronal diversity and their potential role in brain diseases. 
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INTRODUCTION 
  A major challenge in understanding brain development 
and function is the enormous complexity of the central nerv-
ous system (CNS). The complexity of the mammalian brain 
is reflected in the diverse cell types of its neuronal constitu-
ents - their vastly different morphologies, synaptic connec-
tions and functional properties. Recent reviews have dis-
cussed in detail the working definition of a neuronal cell type 
based on various criteria [1, 2] and will not be reiterated 
here. That different neurological diseases result from distinct 
perturbations of specific cell types in the CNS further illus-
trates the precise and highly specialized nature of its neu-
ronal components. For example, in Parkinson’s disease mid-
brain dopaminergic neurons of the substantia nigra are 
acutely sensitive to degeneration in the adult while in the 
pediatric brain tumor medulloblastoma granule neuron pre-
cursors become transformed during development of the 
cerebellum. In each brain disorder, specific genetic muta-
tions are thought to be etiologic in the development of the 
disease. Clearly, no two neuronal populations are created 
equal. How is one to ever make sense of this daunting com-
plexity in order to understand and work towards cures for 
diverse brain diseases? 
  Since the introduction of microarray technology and the 
establishment of the field of functional genomics almost fif-
teen years ago [3-5], researchers around the world have ap-
plied this powerful technology to define the ‘transcriptome’ 
underlying diverse biological phenomena from metabolic   
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growth of single-cell organisms [6] to complex interactions 
between host and virus during infection [7] whereby one can 
monitor gene expression on a genome-wide scale in a single 
experiment. At first glance, microarray technology seemed 
uniquely poised to tackle fundamental questions in the neu-
robiology of disease [8]. However, it has taken a longer time 
for this technology to pervade the neuroscience community 
due to the complex nature of brain tissue and the need to 
overcome technical obstacles such as amplification of start-
ing material from small target areas, a fact that was recog-
nized early on [9,10]. While the first study to amplify line-
arly transcripts from single neurons was published almost 
two decades ago [11], it took some time to optimize this 
method for microarray-based genome-wide expression stud-
ies that require high yields of amplified material. In spite of 
these potentially insurmountable obstacles at that time, the 
power of the microarray as a mechanism to unravel the com-
plexities of the brain was immediately recognized. Indeed, 
an early editorial in Nature Neuroscience suggested that two 
of the most important applications for microarray technology 
in the brain were to identify differences between brain re-
gions and cell types that determine their specific functions 
and connectivity patterns and to document abnormal patterns 
of gene expression in animal models of brain disorders that 
are etiologic in disease [12]. How close (or yet how far) have 
we come to realizing these goals? Interestingly, compared to 
one decade ago when there were only two published studies 
by neurobiologists using microarrays there are now almost 
two thousand references in PubMed with the search criteria 
‘microarray’ and ‘brain’. Clearly, microarray technology is 
much more accessible to the neurobiology community but 
have we been able to answer fundamental questions regard-
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function and disease to a significant extent? To put it bluntly, 
what has gene expression profiling in the brain done for us 
lately? 
  In answering this question, it is critical to understand 
why gene expression profiling in the brain is so important in 
the first place. The human genome contains approximately 
~30,000 genes [13,14] the function of which for the vast 
majority is unknown. Early evidence in rodent models indi-
cated that the brain has increased complexity of gene expres-
sion compared with any other region of the organism (see 
[15] for review). These early findings have been supported 
by analysis of large-scale sequencing projects of human 
brain cDNA libraries in which approximately one third of all 
genes are expressed preferentially in the brain. Because clus-
tering of gene expression profiles groups together efficiently 
genes of known similar function [16], not only will identify-
ing genes and gene expression patterns that underlie this 
complexity of neuronal cell types provide invaluable insight 
in the fundamental organization of the mammalian CNS but 
coregulated expression of genes of known function with 
poorly characterized or novel genes provides a first step in 
the assignment of specific functions of the many genes ex-
pressed in the brain for which information is yet not avail-
able. Together, these methods will allow us to begin to un-
ravel the mysteries of how the dysfunction of specific genes 
and neuronal cell types might lead to diseased states of the 
brain. 
  In the past few years, significant progress has been made 
in our understanding of brain organization by the application 
of functional genomic approaches to characterize gene ex-
pression in defined cell types [1]. In general, such ap-
proaches rely on the labeling and isolation of defined neu-
ronal cell types, the amplification of genetic material, and 
identification of differentially expressed genes (reviewed in 
[2]). In addition, other larger scale approaches not discussed 
in detail here have been complementary to our forward pro-
gress in understanding of gene expression underlying neu-
ronal complexity including the large-scale transgenic-based 
gene expression atlas of the CNS based on bacterial artificial 
chromosomes (GENSAT [17]) and the genome-wide Allen 
Brain Atlas of gene expression in the adult mouse brain [18]. 
These expression based approaches coupled with large scale 
functional approaches such as the trans-NIH initiative 
Knockout Mouse Project (http://www.knockoutmouse.org/) 
to knock-out every gene in the mouse genome will provide 
an amazing database of information to mined with regard to 
understanding candidate genes from expression profiling 
approaches in brain function and disease.  
  Below I provide a review of published studies analyzing 
gene expression in defined neuronal populations or specific 
brain regions with emphasis on recent studies that have led 
to the identification and characterization of candidate genes 
involved in brain function and disease – a goal for which 
expression profiling was expected to have a major impact a 
decade ago. In addition, I highlight novel approaches to ana-
lyze gene expression data and follow-up studies that have 
moved beyond the usual end-point of generating lists of can-
didate genes. 
 
EXPRESSION PROFILING OF BRAIN REGIONS IN 
NORMAL AND DISEASED TISSUES 
  From the beginning, reports of gene expression profiling 
in human brain tissues revealed interesting insights into dis-
eases of the brain. For example, gene expression profiling of 
prefrontal cortical tissue from age-matched pairs of schizo-
phrenic and control subjects showed a decrease in messages 
encoding proteins involved in the regulation of presynaptic 
function correlated with the schizophrenia subjects [19]. The 
basic assumption for this and other studies is that variation in 
gene expression is an important mechanism underlying sus-
ceptibility to complex diseases such as schizophrenia. This 
study led to the demonstration that the transcript encoding 
regulator of G-protein signaling 4 (RGS4) was consistently 
and significantly decreased in the prefrontal cortex of all 
schizophrenic subjects examined [20], suggesting that de-
creased RGS4 expression thereby affecting neuronal signal-
ing might be a distinct feature of schizophrenia. Satisfyingly, 
initial evidence for linkage with schizophrenia was reported 
near RGS4 and several association studies also suggested 
modest associations for certain RGS4 gene variants (see [21] 
for one association study example). However, follow-up 
studies have yielded conflicting and even negative results, 
which has complicated the significance of this candidate 
gene. A possible explanation of the discrepancies is that 
RGS4 variants might modulate endophenotypes (measurable 
components expressed as quantitative traits along the path-
way to development of the full-blown disease) associated 
with schizophrenia rather than risk of disease itself [22]. For 
instance, certain RGS4 polymorphisms appear to contribute 
to structural alterations in brain areas previously associated 
with schizophrenia [23, 24]. While we are far from a clear 
understanding the potential role of RGS4 in schizophrenia, 
its identification as a candidate gene with gene expression 
profiling demonstrates the potential impact of applying mi-
croarray technology to the brain but highlights the need for 
extensive follow-up studies to characterize the function of 
the candidate genes identified in the biological processes in 
which they are implicated.  
  In general, gene expression studies aimed at identifying 
transcripts present in subsets of neurons or expressed at low 
levels are complicated by the cellular heterogeneity of the 
brain [25]. For example, an early study by Sandberg and 
colleagues analyzed baseline gene expression differences in 
six brain regions (cortex, hippocampus, amygdala, entorhinal 
cortex, midbrain, and cerebellum) and found that the his-
tologically less complex cerebellum showed many more 
uniquely expressed genes than the cerebral cortex or hippo-
campus [26] most likely due to the detection limit of mi-
croarray experiments at that time. Moreover, a larger prob-
lem exists in that the expression profile of any given gene 
from a complex tissue such as the brain reflects the transcript 
level within most likely more than one cell type. 
  This general issue led to the application of biostatistical 
approaches such as linear modeling and regression analysis 
of microarray data to ‘deconvolute’ expression profiles de-
rived from whole brain regions [27]. In this study, the 
authors analyzed gene expression in the developing mouse 
pontocerebellar projection system in wild type animals and  
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in mouse lines with mutations known to affect specific cell 
types in the cerebellum. The expression profile for each gene 
was calculated by linear combination of the regression out-
put resulting in the ‘X statistic,’ that is, a quantitative meas-
ure of gene expression differences in specific cell types [27]. 
The combination of gene expression profiling and genetic 
mutant analysis coupled with sophisticated statistical analy-
sis allowed the ability to dissect gene expression programs 
underlying differentiation of specific cell types (Purkinje 
neurons, granule neurons, and glia) within a complex brain 
tissue, the cerebellum.  
  Ultimately, this study identified groups of genes repre-
senting the early specification of granule neuron precursors 
(GNPs), the proliferation of this cellular pool, and finally the 
later stages of granule neuron differentiation [27]. While 
several genes were already known to function in granule 
neuron development providing important validation of the 
approach, a large number of genes had not been previously 
implicated in neural development. For example, expansion 
of the GNP pool occurs during early postnatal development 
and is regulated by Nmyc [28, 29] as part of the sonic 
hedgehog (Shh) signaling pathway [30]. The approach by 
Diaz and colleagues identified genes transiently upregulated 
during GNP proliferation with profiles similar to those of 
known Shh target genes such as Cyclin D2 [27]. One of 
these genes with a high X-statistic value encoded the tran-
scription factor Mad3, a member of the Myc/Max/Mad fam-
ily of transcriptional regulators [31]. Recent evidence born 
out of the expression profiling approach demonstrated a 
novel role for Mad3 in promoting Shh-mediated GNP prolif-
eration [32], providing important functional validation of the 
microarray study. This study is particularly noteworthy in 
light of current models for Mad function that postulate that 
Mad proteins promote differentiation by antagonizing Nmyc-
mediated proliferation [33]. That is, the unbiased nature of 
the expression profiling approach predicted a role for Mad3 
in a biological pathway that would not have been expected 
otherwise.  
  With regard to brain disease, previous studies showed 
that aberrant Shh signaling contributes to cerebellar tumors 
in both mice and humans [34] and Nmyc is an essential 
downstream effector of Shh signaling during both normal 
and neoplastic cerebellar growth [35]. Interestingly, Mad3 is 
upregulated in mouse models of medulloblastoma [32] as 
well as human medulloblastoma samples [36], suggesting 
that like Nmyc (which coincidently was initially identified in 
an expression profiling study of purified GNPs treated with 
Shh [29]), Mad3 might play a role in tumor biogenesis. Fur-
ther studies with genetically modified animals will be neces-
sary to test this possibility directly. 
  More recently, other bioinformatics methods such as sys-
tems biological approaches have been developed to identify 
groups of genes, or ‘modules’, with highly correlated expres-
sion levels in brain regions [37]. To define these modules, 
the authors used a statistical approach called weighted gene 
coexpression network analysis (WGCNA) in which a pair-
wise correlation matrix is calculated for all expressed genes 
and then these correlation measurements are weighted to 
determine the coexpression strength between genes with the 
final output being a transcript network where genes are 
grouped based on their dependence on each other [38]. In 
contrast to the identification of differentially expressed genes 
between brain regions, this strategy takes advantage of the 
inherent variability associated with gene expression profiles 
that exist within brain regions – that is, biological replicates 
from a single brain region - to define higher-order relation-
ships among gene products. Using this approach, Oldham 
and colleagues defined gene coexpression relationships in 
microarray studies generated from specific human brain re-
gions. Comparison of conserved gene modules from differ-
ent brain regions then led to the identification of coexpressed 
genes that correspond to distinct cell types including neu-
rons, oligodendrocytes, astrocytes and microglia [37], dem-
onstrating that cell type-specific information can be identi-
fied from whole brain tissue with this approach.  
  The application of WGCNA to normal and diseased brain 
might then provide a means to reveal biological relationships 
of the phenotypic source of the observed transcriptome 
changes not apparent with traditional analysis of differential 
gene expression. For example, despite the fact that Alz-
heimer’s disease is the most common and well studied neu-
rological disorder of the elderly, no coherent picture of the 
pathology underlying this disease has emerged from previ-
ous microarray expression studies in part due to artifacts 
associated with collection of postmortem samples or with 
different microarray platforms often resulting in non-
overlapping gene lists [8]. Miller and colleagues applied 
WGCNA to existing expression data composed of post-
morten tissue during Alzheimer’s disease progression and 
identified twelve distinct coexpression modules implicated in 
synaptic function, immune response, and metabolism [39]. 
Comparison with gene expression data from normal aging in 
the brain allowed the identification of modules conserved 
between the two states [39], suggesting that common patho-
physiological processes underlie aspects of Alzheimer’s dis-
ease progression and normal aging. A particular strength of 
the approach is the identification of ‘hub’ genes that occupy 
key positions in coexpression modules correlated with Alz-
heimer’s disease progression [39]; thus, understanding the 
role of such hub genes in follow-up studies might provide 
novel insights into the disease as well as their role in normal 
aging. However, while the WGCNA modules identified are 
currently limited to the major cell classes in the brain, ex-
pansion of the WGCNA analysis to include large more pre-
cise transcriptome profiles corresponding to isolated popula-
tions of neurons from normal and diseased samples should 
allow the refinement of the existing modules into neuronal 
subtype-specific classifications in normal brain and during 
disease progression. 
EXPRESSION PROFILING OF ISOLATED NEU-
RONAL CELL TYPES IN NORMAL AND DISEASED 
BRAIN 
  In addition to bioinformatics approaches, other avenues 
of research were applied early on to understand gene expres-
sion in neuronal cell types. Early reports were successful in 
generating expression profiles from single neurons isolated 
by laser capture microdissection (LCM) for microarray ex-
pression analysis [40, 41]; however, the overall quality of the 
expression profiling dataset decreases substantially. Recent 
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reliable and reproducible analysis of single cells. Esumi and 
colleagues developed a combined PCR and T7 RNA polym-
erase amplification technique for gene expression analysis at 
the single cell level [42]. With this approach, the authors 
analyzed single GABAergic neurons progenitors isolated 
from the neocortex of GAD67-GFP knock-in mice by disso-
ciation and aspiration of GFP-positive cells and demon-
strated robust results from microarray expression analysis. 
  An alternative strategy to circumvent the need to analyze 
individual cells is to isolate pools of defined neuronal sub-
types labeled by transgenic or tracer injection methods (re-
viewed in [2]). For instance, Sugino and colleagues carried 
out microarray expression analysis of twelve populations of 
defined neuronal cell types labeled with fluorescent proteins 
in transgenic mice or with stereotaxic injection of fluorescent 
tracers and then isolated cells from adult mouse forebrain by 
manual sorting techniques [43]. Using these expression pro-
files, the authors were able to generate a dendrogram that 
reflected the expected major subdivisions between these 
populations, such as the distinction between cortical in-
terneurons and projection neurons. The strength of this ap-
proach is that it relies on a single measurement, gene expres-
sion distance, to incorporate information over a wide range 
of cellular functions and can be used to compare any two 
neuronal populations on a defined set of variables. In addi-
tion to the classification of unknown neuronal subtypes, this 
dataset should also be useful for the identification of neu-
ronal subtypes specifically altered during disease progres-
sion. Indeed, by measuring the strength of the gene expres-
sion distance between normal neuronal cell types and cells 
during disease progression one might be able to identify spe-
cific biomarkers corresponding to distinct phases of disease 
progression that could serve a clinical value. 
  In addition, other methods such as fluorescent activated 
cell sorting (FACS) have been used successfully to isolate 
labeled neuronal cell types (reviewed in [2]). For example, 
an elegant study by Arlotta and colleagues used FACS to 
isolate corticospinal motor neurons (CSMN) retrogradely 
labeled by injecting microspheres coated with fluorescent 
tracer into their axonal projection fields at distinct stages of 
development in vivo and compared their gene expression to 
two other pure populations of cortical projection neurons: 
callosal projection neurons and corticotectal projection neu-
rons [44]. The identified gene expression profiles predicted 
which genes might play instructive roles in CSMN develop-
ment. Indeed, the authors demonstrated that one of the newly 
identified candidate genes (Ctip2) plays a critical role in the 
development of CSMN axonal projections to the spinal cord 
with loss-of-function experiments in null mutant mice for 
Ctip2 [44], providing impressive validation of their experi-
mental approach to identify key genetic determinants of the 
CSMN population. 
  In more recent studies, these same authors then went on 
to show that Ctip2 also plays a role in striatal medium spiny 
neurons (MSN) differentiation and development [45]. MSNs 
are important for motor control and their degeneration is a 
principal aspect of Hungtington’s disease. In the striatum of 
Ctip2 null mice, MSNs exhibit defects in neuronal differen-
tiation as evidenced by decreased expression of known MSN 
marker genes [45]. Interestingly, the cellular architecture of 
the striatum is dramatically altered as MSNs fail to form into 
a patch-matrix organization, thereby leading to abnormal 
innervation of the striatum by dopaminergic inputs [45]. 
While the role of Ctip2 in Huntington’s disease itself is un-
known, its role in normal development of MSNs warrants 
further study of this gene in progression of this disease. 
  Other studies have pursued similar methods to isolate 
defined neuronal populations using FACS but with different 
methods to label the cells (reviewed in [2]). For example, 
Lobo and colleagues developed a method to purify geneti-
cally labeled neurons from the GENSAT BAC transgenic 
mice for gene expression profiling [46]. Using this approach, 
the authors identified a new set of differentially expressed 
genes in the striatonigral and striatopallidal neurons from 
juvenile and adult mice, two functionally and clinically im-
portant projection neuron subtypes in the basal ganglia. Im-
portantly, the authors provided functional validation of their 
expression profiling approach by demonstrating that Ebf1 is 
a lineage-specific transcription factor essential to the differ-
entiation of striatonigral neurons [46].  
  The results of this study might impact brain disorders of 
the basal ganglia by the identification of candidate genes to 
follow-up on in future studies. Interestingly, two of the most 
promising identified genes (Dock3 and Slc35d3) have some 
known association with movement disorders. Dock3 has 
been implicated in one family with an attention deficit and 
hyperactivity disorder (ADHD)-like clinical syndrome [47] 
while Slc35d3 might function in striatonigral-specific protein 
glycosylation potentially implicated in the childhood hy-
perkinetic movement disorder Sydenham chorea of which 
the pathophysiology is linked to antibodies that recognize 
sugar moieties of glycoproteins on MSNs [48]. While this 
study only provides an initial suggestion of a potential im-
pact into our understanding of movement disorders, the iden-
tification of these and other candidate genes clearly deserves 
further study. 
  A common concern for using approaches such as FACS 
and LCM is that these cell isolation techniques themselves 
might actually introduce variability into the resulting expres-
sion data. It will be useful therefore to compare the results 
from studies utilizing different approaches to isolate samples 
but from the same brain region and disease. For example, 
Parkinson's disease is caused by a progressive loss of the 
midbrain dopamine (DA) neurons in the substantia nigra. 
Moran and colleagues analyzed brain tissue from clinically 
well-documented and pathologically documented cases of 
sporadic Parkinson's disease to define expression profiles 
corresponding to medial and lateral substantia nigra [49]. 
After extensive brain tissue-based validation and additional 
data analysis, the authors then refined their analysis to iden-
tify a list of 892 highly dysregulated ‘priority genes’ hy-
pothesized to form the core of the diseased Parkinsonian 
metabolic network [50].  
  In contrast, Simunovic and colleagues used LCM to iso-
late dopaminergic neurons from the substantia nigra of con-
trol subjects and individuals with idiopathic Parkinson's dis-
ease matched for age and postmortem interval followed by 
microarray analysis to document gene expression changes 
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  Both studies identified genes previously implicated in 
Parkinson’s disease based on published literature [50, 51]. In 
terms of new biological insights into the progression of Park-
inson’s disease, the study by Moran and colleagues identi-
fied biological associations of Parkinson’s disease with can-
cer, diabetes and inflammation [50] while the study by Su-
minovic and colleagues implicated genes involved in synap-
tic activity such as ion channel receptors [51]. However, the 
only overlap between these two studies was the dysregula-
tion of multiple genes associated with programmed cell 
death [50, 51]. Because neither of these studies demonstrated 
a functional role for an identified candidate gene implicated 
in Parkinson’s disease, it is premature to declare which ap-
proach is more robust. Indeed, since the application of 
WGCNA to large datasets appears to be independent of plat-
form and sample collection, this approach might provide a 
way to unify the various candidate gene lists generated by 
expression profiling in these and other studies conducted 
during the past decade. 
OTHER APPROACHES FOR ANALYZING GENE 
EXPRESSION IN NEURONAL CELL TYPES 
  A particularly interesting idea is to molecularly ‘tag’ the 
mRNA population within a defined neuronal subtype to al-
low selective analysis of a particular cell type of interest. For 
example, Von Stetina and colleagues profiled gene expres-
sion throughout the nervous system in worms by generating 
a stable, chromosomally integrated transgenic line express-
ing an epitope-tagged poly-A binding protein throughout the 
nervous system [52]. Such tagged mRNA could then be iso-
lated by immunoprecipitation for cell-specific transcripts. 
Unfortunately, this approach would not be feasible for stud-
ies utilizing postmorten human brain tissue. However, this 
approach could readily be adapted to mice by taking advan-
tage of large-scale transgenic approaches such as GENSAT 
[17] and the Allen Brain Atlas [18] to express epitope-tagged 
poly-A binding protein under cell type specific promoters 
and then crossing these transgenic animals with mouse mod-
els of brain disease. 
  In addition, deep sequencing methods allow direct ultra-
high-throughput sequencing of RNA, which can then be 
mapped back to the genome (reviewed in [53]). However, it 
is important to keep in mind that these sequencing machines 
produce terabytes of data on a daily basis, and thus, make 
profound demands on bioinformatic capabilities for data 
storage and assembly of sequence information for individual 
labs. Furthermore, the inherent short reads generated by 
these methods pose significant problems for the interpreta-
tion of transcripts arising from gene families with high ho-
mology or repetitive regions of the genome, a problem that 
will be particularly evident in the brain with numerous fam-
ily members expressed in distinct and overlapping subsets of 
neuronal cell types. Nevertheless, it can be anticipated that 
by the end of this decade, if not sooner, many studies will 
rely on this technology for large-scale analysis of gene ex-
pression in the brain. 
CONCLUSIONS AND FUTURE DIRECTIONS  
  The past decade has witnessed three orders of magnitude 
increase in the information available regarding microarrays 
and gene expression in the brain. While we have just begun 
to make significant inroads into the characterization of can-
didate genes identified in the various expression profiling 
studies, clear evidence emerges demonstrating the potential 
impact of these and other approaches. However, moving 
from gene lists, coexpression modules, or ‘hub’ genes to 
function in brain disorders still remains a major challenge in 
most expression profiling studies. Transcriptome studies by 
definition are correlation based, not causative. Thus, re-
searchers pursuing expression studies should first have a 
plan mapped out for future research to determine how one 
will demonstrate function of potential candidate genes iden-
tified in their experiments. 
  A particularly important avenue of future research is the 
simultaneous genome-wide analysis of gene expression and 
genetic variation to map genetic factors that underlie indi-
vidual differences in quantitative levels of expression (ex-
pression QTLs or eQTLs; [54]). In the eQTL method, gene 
expression profiles are treated as quantitative traits and ge-
nome-wide association or linkage mapping is performed to 
localize regulatory elements that affect the expression of the 
corresponding differentially expressed gene. The underlying 
rationale is that if a regulatory element coincides with the 
known location of the differentially expressed gene, it most 
likely represents a cis-acting regulatory element, whereas a 
regulatory element identified at a different location most 
likely represents a trans-acting regulatory element. The 
availability of systematically generated eQTL information 
could provide immediate insight into a biological basis for 
disease associations identified through association studies, 
and might allow the identification of gene networks underly-
ing disease pathogenesis. 
  Even though to date there are no publications utilizing 
this methodology to identify genes that influence brain dis-
ease progression, a modification of this method has been 
applied to mouse inbred strains to identify genes that influ-
ence the volume of the amygdala, a brain region that regu-
lates emotion [55]. In this work, amygdala volume was first 
quantified across various mouse strains and traditional QTL 
mapping was then carried out by linkage analysis to identify 
loci that affect phenotype. Next, to prioritize the search for 
candidate genes located within a linkage interval, whole 
brain gene expression levels of the studied strains were 
treated as complex traits, and their covariance with the neu-
roanatomical traits was analyzed to identify genetic loci that 
influence the expression of differentially expressed genes 
[55]. Several genes were found to have expression levels that 
correlate with the size of the amygdala across the studied 
strains [55], suggesting that they can be considered as possi-
ble candidate genes that regulate the anatomical phenotype. 
Therefore, by assessing which genes have expression pat-
terns that correlate with brain disease and by mapping regu-
latory elements for these differentially expressed genes, it 
might be possible to find disease related regulatory networks 
in specific brain regions. However, since many regulatory 
networks are highly brain region specific it will be important 
to conduct eQTL mapping studies using data from brain re-
gions or isolated cell types that are physiologically and phe-
notypically relevant to the trait of interest as those methods 
described in this review. Expression Profiling in the Brain  Current Genomics, 2009, Vol. 10, No. 5    323 
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